Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE)
NCT07266090Phase 2Active, not recruiting
- Sponsor
- Viatris
- Start
- Jan 2026
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cenerimod in systemic lupus erythematosus (SLE), sponsored by Viatris. Primary endpoints: Number of participants with treatment-emergent adverse events, Occurrence of adverse events leading to permanent discontinuation of study treatment at 12 months and 12 more. Started Jan 2026; status: active, not recruiting.
02
Drugs
cenerimod
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07266090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07266090.